TARS · Insider Trading
Tarsus Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by TARS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-17 | Bobak R. Azamian | President/CEO and Board Chair | Sell | −10,000 | −$803.10K |
| 2026-11-05 | Neera Clase | Chief Commercial Officer | A | +17,265 deriv. | — |
| 2026-09-17 | Wendy L Yarno | Director | M | +302 | — |
| 2026-09-17 | David E I Pyott | Director | M | +201 | — |
| 2026-09-17 | William J Phd Link | Director | MIXED | −12,299 | −$979.74K |
| 2026-09-09 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | −13,953 | −$1.22M |
| 2026-09-09 | Bobak R. Azamian | President/CEO and Board Chair | Sell | −10,000 | −$905.60K |
| 2026-09-09 | Seshadri Neervannan | Chief Operating Officer | Sell | −4,564 | −$387.94K |
| 2026-09-03 | Bobak R. Azamian | President/CEO and Board Chair | Sell | −10,000 | −$800.60K |
| 2026-09-03 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | −11,578 | −$897.99K |
| 2026-06-29 | Bhaskar Chaudhuri | Director | A | +6,254 deriv. | — |
| 2026-06-29 | Scott W Morrison | Director | A | +6,254 deriv. | — |
| 2026-06-29 | David E I Pyott | Director | A | +7,060 deriv. | — |
| 2026-06-29 | Katherine Goodrich | Director | A | +6,254 deriv. | — |
| 2026-06-29 | Andrew D. Goldberg | Director | A | +6,254 deriv. | — |
| 2026-06-29 | William J Phd Link | Director | A | +7,060 deriv. | — |
| 2026-06-29 | Wendy L Yarno | Director | A | +7,463 deriv. | — |
| 2026-06-22 | Bobak R. Azamian | President/CEO and Board Chair | Sell | −10,000 | −$615.49K |
| 2026-06-17 | Jeffrey S Farrow | See Remarks | MIXED | +13,485 | −$877.44K |
| 2026-06-17 | William J Phd Link | Director | Sell | −12,500 | −$776.50K |
| 2026-06-17 | Katherine Goodrich | Director | Sell | −2,954 | −$183.38K |
| 2026-06-16 | Andrew D. Goldberg | Director | M | +2,954 | — |
| 2026-06-16 | Bhaskar Chaudhuri | Director | M | +2,954 | — |
| 2026-06-16 | Scott W Morrison | Director | M | +2,954 | — |
| 2026-06-16 | William J Phd Link | Director | M | +2,954 | — |
| 2026-06-16 | Wendy L Yarno | Director | M | +2,954 | — |
| 2026-06-16 | Katherine Goodrich | Director | M | +2,954 | — |
| 2026-04-28 | David E I Pyott | Director | M | +1,383 | — |
| 2026-03-24 | Seshadri Neervannan | Chief Operating Officer | Sell | −2,989 | −$199.52K |
| 2026-03-19 | Bryan Wahl | General Counsel | Sell | −12,440 | −$850.42K |
| 2026-03-19 | Seshadri Neervannan | Chief Operating Officer | Sell | −11,324 | −$772.44K |
| 2026-03-19 | Dianne C. Whitfield | Chief Human Resources Officer | Sell | −12,274 | −$839.07K |
| 2026-03-19 | Jeffrey S Farrow | See Remarks | Sell | −6,430 | −$439.57K |
| 2026-03-19 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | −1,144 | −$78.20K |
| 2026-03-19 | Aziz Mottiwala | Chief Commercial Officer | Sell | −13,056 | −$892.53K |
| 2026-03-19 | Bobak R. Azamian | President/CEO and Board Chair | Sell | −34,603 | −$2.36M |
| 2026-03-18 | William J Phd Link | Director | Sell | −12,500 | −$859.82K |
| 2026-03-17 | Jeffrey S Farrow | See Remarks | M | +13,042 | — |
| 2026-03-17 | Bryan Wahl | General Counsel | M | +24,236 | — |
| 2026-03-17 | Dianne C. Whitfield | Chief Human Resources Officer | M | +23,909 | — |
| 2026-03-17 | Aziz Mottiwala | Chief Commercial Officer | M | +26,482 | — |
| 2026-03-17 | Elizabeth Yeu Lin | Chief Medical Officer | M | +2,511 | — |
| 2026-03-17 | Bobak R. Azamian | President/CEO and Board Chair | M | +66,274 | — |
| 2026-03-17 | Seshadri Neervannan | Chief Operating Officer | M | +26,287 | — |
| 2026-03-09 | Jeffrey S Farrow | See Remarks | A | +50,030 deriv. | — |
| 2026-03-09 | Elizabeth Yeu Lin | Chief Medical Officer | A | +44,471 deriv. | — |
| 2026-03-09 | Bobak R. Azamian | President/CEO and Board Chair | A | +157,499 deriv. | — |
| 2026-03-09 | Bryan Wahl | General Counsel | A | +44,471 deriv. | — |
| 2026-03-09 | Seshadri Neervannan | Chief Operating Officer | A | +44,471 deriv. | — |
| 2026-03-09 | Dianne C. Whitfield | Chief Human Resources Officer | A | +44,471 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bobak R. Azamian | President/CEO and Board Chair | 851,412 | $66.32M |
| William J Phd Link | Director | 94,487 | $7.36M |
| Seshadri Neervannan | Chief Operating Officer | 79,007 | $6.15M |
| Bryan Wahl | General Counsel | 63,959 | $4.98M |
| Aziz Mottiwala | Chief Commercial Officer | 61,480 | $4.79M |
| Jeffrey S Farrow | See Remarks | 56,801 | $4.42M |
| Dianne C. Whitfield | Chief Human Resources Officer | 35,028 | $2.73M |
| Andrew D. Goldberg | Director | 19,654 | $1.53M |
| Wendy L Yarno | Director | 16,956 | $1.32M |
| Elizabeth Yeu Lin | Chief Medical Officer | 16,177 | $1.26M |
| Scott W Morrison | Director | 13,654 | $1.06M |
| Bhaskar Chaudhuri | Director | 11,654 | $907.73K |
| David E I Pyott | Director | 10,958 | $853.52K |
| Katherine Goodrich | Director | 2,233 | $173.93K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TARS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.